Lomitapide mesylate
CAS: 202914-84-9
Ref. 3D-CIA91484
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire | ||
| 250mg | To inquire |
Product Information
- 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]car bonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate
- 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate
- 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate (1:?)
- BMS 201038 methanesulfonic acid salt
- Bms 201038-04
- Juxtapid
Lomitapide mesylate is a drug used to treat familial hypercholesterolemia. It is an ATP-binding cassette transporter inhibitor and can be used to lower cholesterol levels in patients with homozygous familial hypercholesterolemia. Lomitapide mesylate has been shown to reduce LDL-C levels by up to 50% in patients with this condition. The drug has a number of side effects, such as skin cancer, which may be due to the inhibition of chemoattractant protein signalling pathways. Side effects are usually mild and transient, but may include hepatic dysfunction and metabolic disorders. Lomitapide mesylate is metabolized by CYP3A4 enzyme and its plasma concentration may be increased if taken concurrently with drugs that inhibit this enzyme (e.g., diltiazem).
Chemical properties
Technical inquiry about: 3D-CIA91484 Lomitapide mesylate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
